Revenue and profit declined year-over-year amid increased R&D investment, but licence fee income surged on major global deals. Multiple new drug approvals, robust pipeline progress, and a record AstraZeneca partnership highlight ongoing innovation and global expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.